Bifidobacterium animalis subsp. lactis (BB-12 / HN019)

Bifidobacterium animalis subsp. lactis
Evidence Level
Strong
3 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

Bifidobacterium animalis subsp. lactis is one of the two most-studied probiotic strains globally (along with Lactobacillus rhamnosus GG). Two specific strains dominate the clinical literature: BB-12 (developed by Chr. Hansen, used in Activia® yogurt) and HN019 (developed by Fonterra/DuPont, marketed as HOWARU® Bifido). Naturally resistant to acid and bile, B. lactis colonizes the small and large intestine where it ferments dietary fibers into short-chain fatty acids, supports immune function, and improves bowel regularity.

Studied Dose 1–10 billion CFU/day (BB-12); 17.2 billion CFU/day (HN019 in constipation studies)
Active Compound Live Bifidobacterium animalis subsp. lactis BB-12 or HN019 strains

Constipation relief and bowel regularity

A 2017 meta-analysis of 14 RCTs found B. lactis significantly reduces colonic transit time (-12.4 hours), increases stool frequency (+1.5 stools/week), and improves stool consistency in adults with functional constipation. The HN019 strain has the strongest evidence: a 2011 RCT (100 adults, 17.2 billion CFU/day for 14 days) showed 31% improvement in colonic transit time and significant reductions in constipation, abdominal pain, and incomplete evacuation.

Immune function and respiratory infection reduction

Multiple RCTs demonstrate B. lactis enhances immune markers including phagocytic activity of monocytes/neutrophils, NK cell tumoricidal activity, and IgA production. A 6-month RCT in elderly subjects (n=80) found HN019 supplementation reduced incidence of common infections and increased measures of cellular immunity. BB-12 supplementation in infants reduced incidence of acute respiratory infections by ~30%.

Diarrhea prevention in children and elderly

BB-12 (often combined with Streptococcus thermophilus) reduced acute diarrhea incidence in children attending daycare by 50% in a 7-month RCT. In elderly populations, HN019 reduced antibiotic-associated diarrhea and shortened diarrhea duration by 1–2 days when combined with rehydration.

Cholesterol and lipid profile improvement

A 2021 meta-analysis found B. lactis supplementation modestly reduces total cholesterol (-7.8 mg/dL) and LDL cholesterol (-7.3 mg/dL) in adults with mild hypercholesterolemia, with effects more pronounced after 8+ weeks of use. Mechanism involves bile salt hydrolase activity reducing reabsorption of bile acids.

1

Acid and bile resistance enabling robust gut colonization

B. lactis BB-12 and HN019 have exceptional tolerance to gastric acid (pH 2–3) and bile salts (>0.3% concentration) compared to most Bifidobacterium species, which typically die in stomach acid. This allows reliable delivery of viable bacteria to the small and large intestine where they exert their effects.

2

Short-chain fatty acid (SCFA) production via fiber fermentation

B. lactis ferments resistant starches, oligofructose, inulin, and other prebiotic fibers to produce acetate (primary SCFA), propionate, and lactate. These SCFAs lower colonic pH, suppress pathogens, fuel colonocytes (acetate), regulate appetite hormones (propionate via GLP-1/PYY), and inhibit inflammation.

3

Bile salt hydrolase activity for cholesterol reduction

B. lactis produces bile salt hydrolase (BSH) enzymes that deconjugate bile acids in the small intestine. Deconjugated bile acids are less efficiently reabsorbed, forcing the liver to use cholesterol to synthesize new bile acids — a mechanism similar to cholestyramine and other bile acid sequestrants.

4

Tight junction enhancement and gut barrier protection

Increases expression of occludin and zonula occludens-1 (ZO-1) tight junction proteins, reducing intestinal permeability. Particularly important in elderly patients and those with low-grade chronic inflammation, as gut barrier function declines with age.

1
B. lactis HN019 for Functional Constipation — RCT
PubMed

Randomized, double-blind, placebo-controlled trial. 100 adults with functional constipation received HN019 at 17.2 billion CFU/day or placebo for 14 days.

100 adults (aged 18–70) with functional constipation per Rome III criteria.

HN019 reduced colonic transit time by 31% (vs. 9% placebo) and significantly improved stool frequency, stool consistency, completeness of evacuation, and reduction of abdominal pain. Effects observed within 14 days of supplementation.

2
B. lactis HN019 Immune Function in Elderly
PubMed

Double-blind crossover RCT. Elderly volunteers received HN019 in milk daily for 6 weeks, with washout between phases.

30 healthy elderly volunteers (aged 60–90).

Significant increases in phagocytic activity of polymorphonuclear cells (+33%), tumoricidal activity of NK cells (+18%), and IL-2 production. Effects most pronounced in subjects with the lowest baseline immune function — suggesting HN019 may help correct age-related immune decline.

3
BB-12 for Common Infections in Children — Meta-Analysis
PubMed

Systematic review and meta-analysis of 12 RCTs evaluating BB-12 or B. lactis-containing fermented dairy products in children.

4,733 children (mostly attending daycare).

BB-12 supplementation reduced incidence of common acute illnesses (URI, GI infections) by 25–30%. Reduced school/daycare absences by ~20%. Particularly effective at preventing rotaviral diarrhea episodes.

Common Potential side effects

Generally regarded as safe with GRAS status; one of the most extensively safety-studied probiotic strains
Mild bloating or transient gas during initial week of supplementation in 5–10% of users
No serious adverse events reported in clinical trials including pediatric, elderly, and immunocompromised cancer patient populations

Important Drug interactions

Antibiotics — separate by 2+ hours; can be co-administered for AAD prevention
Generally no significant drug interactions; compatible with PPIs, H2 blockers, NSAIDs, statins, anticoagulants
Caution in severely immunocompromised patients (rare bacteremia reports)